39539-66-7

Basic information

• Product Name: 4-Methylpiperazine-1-carbonyl chloride
• Synonyms: METHYL PIPERAZINE CARBAMOYL CHLORIDE;4-METHYL-1-PIPERAZINECARBONYL CHLORIDE;4-METHYL-1-CHLOROCARBONYL PIPERAZINE;4-METHYLPIPERAZINE-1-CARBONYL CHLORIDE;4-METHYLPIPERAZINECARBONYL CHLORIDE;1-Piperazinecarbonyl chloride, 4-methyl- (6CI,9CI);4-Methylpierazine-1-carbonylchloride;4-Methyl-1-piperazinecarbonyl chloride 97%
• CAS NO: 39539-66-7
• Molecular Formula: C₆H₁₁ClN₂O
• Molecular Weight: 162.62
• Product Categories: ACIDHALIDE;Piperazine derivates;API intermediates;Building Blocks;Heterocyclic Building Blocks;Piperazines;Building Blocks;C4 to C8;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 39539-66-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 225-228 °C(lit.)
• Boiling Point: 278-279 °C(lit.)
• Flash Point: >230 °F
• Appearance: Colorless to brown/Liquid
• Density: 1.200 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0256mmHg at 25°C
• Refractive Index: n20/D 1.4980(lit.)
• Storage Temp.: 2-8°C
• PKA: 6.61±0.10(Predicted)
• CAS DataBase Reference: 4-Methylpiperazine-1-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methylpiperazine-1-carbonyl chloride(39539-66-7)
• EPA Substance Registry System: 4-Methylpiperazine-1-carbonyl chloride(39539-66-7)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 39539-66-7(Hazardous Substances Data)

Usage

Description

4-Methylpiperazine-1-carbonyl chloride, also known as 4-Methyl-1-piperazinecarbonyl chloride, is an organic compound that can be synthesized from 1-methylpiperazine by reacting with phosgene. It is a versatile chemical intermediate with potential applications in various industries due to its unique chemical structure and reactivity.

Uses

Used in Pharmaceutical Industry:
4-Methylpiperazine-1-carbonyl chloride is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its ability to react with different functional groups makes it a valuable building block in the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-Methylpiperazine-1-carbonyl chloride serves as a key component in the production of various organic compounds. Its reactivity with other molecules allows for the creation of a wide range of products, including those with potential applications in materials science, agrochemicals, and other specialty chemicals.
Used in Research and Development:
4-Methylpiperazine-1-carbonyl chloride is also utilized in research and development settings, where it can be employed to explore new chemical reactions and investigate the properties of novel compounds. Its unique structure and reactivity make it an interesting candidate for studying various aspects of organic chemistry and potentially discovering new applications in different industries.

InChI:InChI=1/C6H11ClN2O/c1-8-2-4-9(5-3-8)6(7)10/h2-5H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 58226-19-0 1-Piperazinecarboxylic acid, 4-methyl- 
• 55112-42-0 4-methylpiperazine-1-carbonyl chloride monohydrochloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 62226-74-8 1-benzyl-4-methylpiperazine 
• 75-44-5 phosgene 
• 108-88-3 toluene 
• 71-43-2 benzene 
• 67-66-3 chloroform 

Downstream Products

• 43200-80-2 zopiclon 
• 105492-90-8 4-Methyl-piperazine-1-carboxylic acid {4-[4-(7-chloro-quinolin-4-ylamino)-phenyl]-thiazol-2-yl}-amide 

Relevant articles and documents

Dual inhibitors of Interleukin-6 and acetylcholinesterase for treatment of Alzheimer's disease: Design, docking, synthesis and biological evaluation

Multitarget compounds intercept two or more functionally complementary pathways simultaneously, and are therefore considered to have potential in effectively treating complex multifactorial diseases like Alzheimer's disease (AD). In the present study, novel molecules are designed by coupling a chromone and a N,N-disubstituted carbamoyl amine as pharmacophore for interleukin-6 (IL-6) and acetylcholinesterase (AChE) inhibition, respectively. Four series (Y1–Y4) of 40 compounds are designed by using alkyl linkers of different lengths (1–4 carbon atoms) for the coupling of the two selected pharmacophore. Docking of all designed compounds in AChE leads to the identification of twelve best fit compounds (Docking score >8.3). The data suggests that a 1- or 2-carbon atom linker is the most conducive to orient the pharmacophore for optimum binding with AChE active site. The predicted ADME properties of the 12 selected compounds suggest that these can cross the blood brain barrier (BBB) with good oral bioavailability. These compounds are synthesised and evaluated for anti-AChE activity. Five compounds, showing >45% inhibition of AChE, are further evaluated for IL-6 inhibitory activity. Compound Y1f is found to be the most potent inhibitor of both AChE and IL-6 (IC50 0.7 and 0.8 ?μM, respectively). It suggests that a chromone moiety connected to a piperidine ring through a 1-carbon atom linker may provide a useful template to medical chemists for the development of new chemical entities effective against AD.

RAS INHIBITORS

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities

A series of 3-carbamate and 29-ester celastrol derivatives (compounds 1–26) were designed and synthesized. These analogues were evaluated for their cytotoxic activities against several cancer cell lines. Cytotoxicity data revealed that the properties of substituents and substitution position had important influence on cytotoxic activity. Modification of C-3 hydroxyl with size-limited groups did not reduce the activity obviously. The introduction of polarity group like piperazine could improve the solubility. Compound 23 was chosen to further evaluate anti-tumor efficacy in vivo. It showed higher inhibition rate and better safety than celastrol during in vivo experiment by intragastric administration. The preliminary antitumor studies of compound 23 in vivo showed that it might be promising for the development of new antitumor agents.